Original Article

Split Viewer

Korean J Hematol 2011; 46(4):

Published online December 31, 2011

https://doi.org/10.5045/kjh.2011.46.4.244

© The Korean Society of Hematology

Differential effects of CXCR4 antagonists on the survival and proliferation of myeloid leukemia cells in vitro

Ha-Yon Kim1, Ji-Young Hwang1, Yoon-Suk Oh1, Seong-Woo Kim1, Hyo-Jin Lee2, Hwan-Jung Yun2, Samyong Kim2, Young-Jun Yang3, and Deog-Yeon Jo2*

1Department of Medical Science, School of Medicine, Chungnam National University, Daejeon, Korea.

2Department of Internal Medicine, School of Medicine, Chungnam National University, Daejeon, Korea.

3Department of Internal Medicine, Daejeon Saint Mary's Hospital, Daejeon, Korea.

Correspondence to : Correspondence to Deog-Yeon Jo, M.D., Ph.D. Division of Hematology/Oncology, Department of Internal Medicine, Chungnam National University Hospital, 33 Munhwa-ro, Jung-gu, Daejeon 301-721, Korea. Tel: +82-42-280-7162, Fax: +82-42-257-5753, deogyeon@cnu.ac.kr

Received: October 14, 2011; Revised: December 7, 2011; Accepted: December 12, 2011

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Antagonists of CXC chemokine receptor 4 (CXCR4), including AMD3100, induce peripheral mobilization of hematopoietic stem cells and have been approved for clinical use. We explored whether the CXCR4 antagonists affected the survival and proliferation of myeloid leukemia cells in vitro.

Methods

The effects of CXCR4 antagonists AMD3100 and T140 on the survival and proliferation of myeloid leukemia cell lines (U937, HL-60, MO7e, KG1a, and K562) as well as CD34+ cells obtained from patients with AML and CML were analyzed by flow cytometry by using annexin V and a colorimetric cell proliferation assay.

Results

AMD3100, but not T140, stimulated the proliferation of leukemia cells in vitro in a dose-dependent manner for up to 5 days (~2-fold increase at a concentration of 10-5 M), which was not abrogated by pretreatment of the cells with pertussis toxin, but was attenuated by RNAi knockdown of CXCR7 transcripts. In contrast, AMD3100 induced a marked decrease in the cell numbers after 5-7 days. AMD3100, but not T140, induced phosphorylation of MAPK p44/p42. AMD3100 increased the number and size of leukemia cell colonies and reduced cell apoptosis during the first 5-7 days of incubation, but the phenomena were reversed during the later period of incubation.

Conclusion

The effects of CXCR4 antagonists on the proliferation of myeloid leukemia cells are not uniform. AMD3100, but not T140, exerts dual effects, initially enhancing and subsequently inhibiting the survival and proliferation of the cells in vitro.

Keywords AMD3100, CXCR4, SDF-1, Myeloid leukemia, Cell proliferation, Apoptosis

Article

Original Article

Korean J Hematol 2011; 46(4): 244-252

Published online December 31, 2011 https://doi.org/10.5045/kjh.2011.46.4.244

Copyright © The Korean Society of Hematology.

Differential effects of CXCR4 antagonists on the survival and proliferation of myeloid leukemia cells in vitro

Ha-Yon Kim1, Ji-Young Hwang1, Yoon-Suk Oh1, Seong-Woo Kim1, Hyo-Jin Lee2, Hwan-Jung Yun2, Samyong Kim2, Young-Jun Yang3, and Deog-Yeon Jo2*

1Department of Medical Science, School of Medicine, Chungnam National University, Daejeon, Korea.

2Department of Internal Medicine, School of Medicine, Chungnam National University, Daejeon, Korea.

3Department of Internal Medicine, Daejeon Saint Mary's Hospital, Daejeon, Korea.

Correspondence to:Correspondence to Deog-Yeon Jo, M.D., Ph.D. Division of Hematology/Oncology, Department of Internal Medicine, Chungnam National University Hospital, 33 Munhwa-ro, Jung-gu, Daejeon 301-721, Korea. Tel: +82-42-280-7162, Fax: +82-42-257-5753, deogyeon@cnu.ac.kr

Received: October 14, 2011; Revised: December 7, 2011; Accepted: December 12, 2011

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Antagonists of CXC chemokine receptor 4 (CXCR4), including AMD3100, induce peripheral mobilization of hematopoietic stem cells and have been approved for clinical use. We explored whether the CXCR4 antagonists affected the survival and proliferation of myeloid leukemia cells in vitro.

Methods

The effects of CXCR4 antagonists AMD3100 and T140 on the survival and proliferation of myeloid leukemia cell lines (U937, HL-60, MO7e, KG1a, and K562) as well as CD34+ cells obtained from patients with AML and CML were analyzed by flow cytometry by using annexin V and a colorimetric cell proliferation assay.

Results

AMD3100, but not T140, stimulated the proliferation of leukemia cells in vitro in a dose-dependent manner for up to 5 days (~2-fold increase at a concentration of 10-5 M), which was not abrogated by pretreatment of the cells with pertussis toxin, but was attenuated by RNAi knockdown of CXCR7 transcripts. In contrast, AMD3100 induced a marked decrease in the cell numbers after 5-7 days. AMD3100, but not T140, induced phosphorylation of MAPK p44/p42. AMD3100 increased the number and size of leukemia cell colonies and reduced cell apoptosis during the first 5-7 days of incubation, but the phenomena were reversed during the later period of incubation.

Conclusion

The effects of CXCR4 antagonists on the proliferation of myeloid leukemia cells are not uniform. AMD3100, but not T140, exerts dual effects, initially enhancing and subsequently inhibiting the survival and proliferation of the cells in vitro.

Keywords: AMD3100, CXCR4, SDF-1, Myeloid leukemia, Cell proliferation, Apoptosis

Fig 1.

Figure 1.

AMD3100 and T140 inhibit the SDF-1-induced chemotaxis of myeloid leukemia cells, and trigger the internalization of surface CXCR4. (A) Four-hour transmigration of MO7e cells towards SDF-1 (200 ng/mL). AMD3100 and T140 were added at concentrations of 10-5 M and 10-6 M, respectively. a)P<0.05, compared to the control. (B) U937 cells were incubated with or without 10-5 M AMD3100 and 10-6 M T140, respectively, for 3 hr and subsequently subjected to flow cytometry.

Blood Research 2011; 46: 244-252https://doi.org/10.5045/kjh.2011.46.4.244

Fig 2.

Figure 2.

AMD3100 stimulates the proliferation of myeloid leukemia cells. Cells were incubated in the presence of AMD3100 (A) or T140 (B) for up to 72 hr. (C) Bone marrow CD34+ cells from 3 each patients with AML and CML were incubated in the presence of AMD3100 (10-5 M) for 72 hr. (D) U937 cells were incubated with AMD3100 (10-5 M). As indicated, the cells were pretreated with pertussis toxin (PTX) for 2 hr before the incubation. (E) U937 cells were incubated in X-VIVO medium with or without AMD3100 (10-5 M) and subsequently subjected to cell cycle analysis. (F) U937 cells were incubated in RPMI-1640 medium without serum in the presence or absence of AMD3100 (10-5 M) for 72 hr, stained with annexin V and propidium iodide (PI), and subjected to flow cytometry. Representative flow cytometry profiles are shown in the left panel. In the right panel, the percentages of the annexin V-positive apoptotic cells are presented a)P<0.05, compared with the control.

Blood Research 2011; 46: 244-252https://doi.org/10.5045/kjh.2011.46.4.244

Fig 3.

Figure 3.

AMD3100 induces the phosphorylation of SDF-1-linked signaling molecules. (A) MO7e cells were incubated with AMD3100 (10-5 M) and subsequently subjected to western blot analysis. Representative results of 3 experiments are shown. (B) U937 cells were treated with 10-5 M AMD3100, 10 µM LY294002, 100 nM wortmannin, 50 µM PD98059, 10 µM AG490, 50 nM rapamycin, and 10 µM SB203580 for 3 days.

Blood Research 2011; 46: 244-252https://doi.org/10.5045/kjh.2011.46.4.244

Fig 4.

Figure 4.

Survival of leukemia cells in an extended period of culture. (A) HL-60 cells (a), K562 cells (b), KG1a cells (c), and U937 cells (d) were incubated with AMD3100 (10-7 M to 10-5 M) for up to 14 days. Data are representative results of 3 or more independent experiments showing similar results. (B) Effects of AMD3100 on the formation of tumor cell colonies were examined using K562 cells. Representative profiles of the colony assay are shown.

Blood Research 2011; 46: 244-252https://doi.org/10.5045/kjh.2011.46.4.244

Fig 5.

Figure 5.

Myeloid leukemia cells express CXCR7 on the cell surface, which is internalized by AMD3100. (A) Representative profiles of CXCR7 expression on the cell surface. (B) U937 cells were incubated with 10-5 M AMD3100 and 10-5 M T140, respectively, for 3 hr and subsequently subjected to flow cytometry.

Blood Research 2011; 46: 244-252https://doi.org/10.5045/kjh.2011.46.4.244

Fig 6.

Figure 6.

Knockdown of CXCR7, but not CXCR4, delays the proliferation enhancement induced by AMD3100. U937 cells were transfected with 25 nM CXCR4 siRNA or 5 nM CXCR7 siRNA and were further incubated in serum-free medium in the presence or absence of AMD3100 for up to 3 days. (A) Representative profiles of the decrease in cell surface expression of CXCR4 and CXCR7 induced by siRNA. (B) Representative results of proliferation of the CXCR4 siRNA-transfected cells among 3 or more independent experiments showing similar results. (C) Representative results of the proliferation of the CXCR7 siRNA-transfected cells among 3 or more independent experiments showing similar results.

Blood Research 2011; 46: 244-252https://doi.org/10.5045/kjh.2011.46.4.244
Blood Res
Volume 59 2024

Stats or Metrics

Share this article on

  • line

Related articles in BR

Blood Research

pISSN 2287-979X
eISSN 2288-0011
qr-code Download